IRulya Therapeutics Inc.
IRLA· Nasdaq
IRLAIRulya Therapeutics Inc.
Filed Nov 12, 2025 · 10-Q · 43 days after period end · 0001193125-25-277529
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Net Income | -$13.44M | -$5.49M | -$5.35M | -$7.92M |
| EPS Diluted | -$0.25 | -$0.13 | -$0.15 | -$0.22 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IRulya Therapeutics Inc. · CIK 1662774 · Engraved from SEC EDGAR
ended Sep 30, 2025 · filed Nov 12, 2025 · 43 d after period end
